Marín J, Marín E, Gutiérrez-Iñiguez M A, Avendaño C, Rodríguez-Martínez M A
Servicio de Farmacología Clínica, Hospital Universitario Clínica Puerta de Hierro, c/ San Martín de Porres, 4, 28035-Madrid, Spain.
Pharmacol Ther. 2000 Oct;88(1):15-31. doi: 10.1016/s0163-7258(00)00076-0.
Congestive heart failure is a complex syndrome and one of the major cardiological problems of our time. It is characterized by an important neurohumoral activation to compensate for the reduction of cardiac output and blood pressure, that worsens the prognosis with time. The aim of the treatment is focused on how to improve the quality of life and how to prolong survival. Usually, treatment, either symptomatic or directed to control the neuroendocrine compensatory changes, is necessary. The drugs currently used are angiotensin-converting enzyme inhibitors, diuretics, digoxin, and beta-adrenoceptor agonists. In addition, new drugs, such as angiotensin II receptor antagonists, beta-adrenoceptor antagonists, ibopamine, Ca(2+) antagonists, neutral endopeptidase inhibitors, vasopressin antagonists, Ca(2+)-sensitizers with cyclic AMP-dependent or -independent mechanisms, and endothelin antagonists, are also being used.
充血性心力衰竭是一种复杂的综合征，也是我们这个时代主要的心脏病学问题之一。其特征是重要的神经体液激活，以代偿心输出量和血压的降低，随着时间的推移，这会使预后恶化。治疗的目的集中在如何提高生活质量以及如何延长生存期。通常，无论是对症治疗还是旨在控制神经内分泌代偿性变化的治疗都是必要的。目前使用的药物有血管紧张素转换酶抑制剂、利尿剂、地高辛和β肾上腺素能受体激动剂。此外，诸如血管紧张素II受体拮抗剂、β肾上腺素能受体拮抗剂、异波帕胺、钙拮抗剂、中性内肽酶抑制剂、血管加压素拮抗剂、具有环磷酸腺苷依赖性或非依赖性机制的钙敏化剂以及内皮素拮抗剂等新药也正在被使用。
